中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

局部栓塞联合靶向免疫综合治疗肝肉瘤样癌1例报告

雷进 张林枝 陆荫英 陈博文 左石

引用本文:
Citation:

局部栓塞联合靶向免疫综合治疗肝肉瘤样癌1例报告

DOI: 10.3969/j.issn.1001-5256.2022.04.026
基金项目: 

贵州省优秀青年科技人才专项基金 (Talents of Guizhou Kehe platform[2019]5647)

伦理学声明:本例报告已获得患者知情同意。
利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:雷进负责资料分析,撰写论文;张林枝、陈博文负责提出具体修改意见并进行修改;左石、陆荫英负责拟定撰写思路,指导文章写作并最终定稿。
详细信息
    通信作者:

    左石,drzuoshi@qq.com

Local embolization combined with targeted comprehensive immunotherapy in treatment of sarcomatoid hepatocellular carcinoma: A case report

Research funding: 

Special Fund for Outstanding Young Scientific and Technological Talents of Guizhou Province (Talents of Guizhou Kehe platform[2019]5647)

More Information
    Corresponding author: ZUO Shi, drzuoshi@qq.com(ORCID: 0000-0001-9092-8723)
  • 图  1  肝穿刺病理结果

    注:a,见多个核大深染肿瘤细胞,部分成梭形(HE染色,×100);b,Vimentin弥漫强阳性(免疫组化,×200);c,CK弥漫强阳性(免疫组化,×200)。

    Figure  1.  Pathological results of liver puncture

    图  2  肝脏增强MRI初诊结果

    注:a,动脉期呈不均匀轻中度强化;b,门静脉期呈不均匀稍低信号;c,稍长T2信号病变;d,DWI轻度高信号。箭头指向均表示HSC病灶。

    Figure  2.  Results of initial diagnosis of liver enhanced MRI

    图  3  MRI复查结果

    注:a,动脉期边缘少许强化,大部未见强化;b,门静脉期病灶边缘呈稍低信号;c,病灶边缘稍长T2信号病变;d,病灶边缘DWI轻度高信号。箭头表示原病灶边缘异常情况。

    Figure  3.  Results of MRI reexamination

    图  4  肝动脉造影结果

    注:a,2021年1月20日第1次肝动脉造影,动脉期肝右动脉远端分支增粗,可见肿瘤血管。b,2021年3月1日第2次肝动脉造影,动脉期肝右动脉远端分支增粗,可见肿瘤血管,但较第1次造影明显减少。c,2021年4月23日第3次肝动脉造影,动脉期肝右动脉肿瘤血管减少。d,2021年4月23日第3次介入术后,未见明显肿瘤血管。箭头均指示肝脏肿瘤血管造影情况。

    Figure  4.  Results of hepatic arteriography

  • [1] WU L, TSILIMIGRAS DI, FAROOQ A, et al. Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis[J]. Cancer, 2019, 125(21): 3767-3775. DOI: 10.1002/cncr.32396.
    [2] GIANNIS D, MORSY S, GEROPOULOS G, et al. The epidemiology, staging and outcomes of sarcomatoid hepatocellular carcinoma: A SEER population analysis[J]. In Vivo, 2021, 35(1): 393-399. DOI: 10.21873/invivo.12270.
    [3] KIM SJ, RHU J, KIM JM, et al. Surgical treatment outcomes of primary hepatic sarcomas: A single-center experience[J]. World J Hepatol, 2021, 13(5): 584-594. DOI: 10.4254/wjh.v13.i5.584.
    [4] ZHANG H, CHAI S, CHEN L, et al. MRI features of hepatic sarcomatoid carcinoma different from hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Front Oncol, 2021, 11: 611738. DOI: 10.3389/fonc.2021.611738.
    [5] WANG QB, CUI BK, WENG JM, et al. Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma and carcinosarcoma of the liver[J]. J Gastrointest Surg, 2012, 16(9): 1715-1726. DOI: 10.1007/s11605-012-1946-y.
    [6] LI Z, WU X, BI X, et al. Clinicopathological features and surgical outcomes of four rare subtypes of primary liver carcinoma[J]. Chin J Cancer Res, 2018, 30(3): 364-372. DOI: 10.21147/j.issn.1000-9604.2018.03.08.
    [7] FORBES A, PORTMANN B, JOHNSON P, et al. Hepatic sarcomas in adults: A review of 25 cases[J]. Gut, 1987, 28(6): 668-674. DOI: 10.1136/gut.28.6.668.
    [8] KIM DK, KIM BR, JEONG JS, et al. Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years[J]. World J Gastroenterol, 2019, 25(5): 608-621. DOI: 10.3748/wjg.v25.i5.608.
    [9] MORISUE R, KOJIMA M, SUZUKI T, et al. Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses[J]. Int J Cancer, 2021, 149(3): 546-560. DOI: 10.1002/ijc.33545.
    [10] ERIGUCHI N, AOYAGI S, OKUDA K, et al. Unusual liver carcinomas with sarcomatous features: Analysis of four cases[J]. Surg Today, 2001, 31(6): 530-533. DOI: 10.1007/s005950170116.
    [11] CHENG JY, WANG CH, CHEN JH, et al. Sarcoma- toid carcinomas of the liver, gallbladder, and pancreas: A clinicopathological portrait and literature review[J]. J Clin Hepatol, 2020, 36(10): 2270-2273. DOI: 10.3969/j.issn.1001-5256.2020.10.022.

    程捷瑶, 王沧海, 陈建宏, 等. 肝胆胰肉瘤样癌的临床病理特征及文献复习[J]. 临床肝胆病杂志, 2020, 36(10): 2270-2273. DOI: 10.3969/j.issn.1001-5256.2020.10.022.
    [12] LUO C, XIN H, YIN D, et al. Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma[J]. Aging (Albany NY), 2021, 13(11): 15126-15138. DOI: 10.18632/aging.203076.
    [13] QIAN XH, GAO BQ, WANG WL. Primary hepatic sarcomatous carcinoma misdiagnosed as liver abscess: A case report[J]. J Clin Hepatol, 2020, 36(1): 158-160. DOI: 10.3969.j.issn.1001-5256.2020.01.035

    钱晓晖, 高炳强, 王伟林. 原发性肝肉瘤样癌误诊为肝脓肿1例报告[J]. 临床肝胆病杂志, 2020, 36(1): 158-160. DOI: 10.3969.j.issn.1001-5256.2020.01.035.
    [14] YANG Z, LV K, ZHAO Y, et al. Sarcomatoid hepatocellular carcinoma mimicking hepatic abscess: A case report[J]. Medicine (Baltimore), 2020, 99(39): e22489. DOI: 10.1097/MD.0000000000022489.
    [15] SHAH V, ARORA A, TYAGI P, et al. Intrahepatic cholangiocarcinoma masquerading as liver abscess[J]. J Clin Exp Hepatol, 2015, 5(1): 89-92. DOI: 10.1016/j.jceh.2014.12.006.
    [16] CHEN LD, RUAN SM, LIANG JY, et al. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound[J]. World J Gastroenterol, 2018, 24(33): 3786-3798. DOI: 10.3748/wjg.v24.i33.3786.
    [17] WEITZ J, KLIMSTRA DS, CYMES K, et al. Management of primary liver sarcomas[J]. Cancer, 2007, 109(7): 1391-1396. DOI: 10.1002/cncr.22530.
    [18] WU Z, WEI Y, CAI Z, et al. Long-term survival outcomes of undifferentiated embryonal sarcoma of the liver: A pooled analysis of 308 patients[J]. ANZ J Surg, 2020, 90(9): 1615-1620. DOI: 10.1111/ans.15684.
    [19] HOOS A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations[J]. Nat Rev Drug Discov, 2016, 15(4): 235-247. DOI: 10.1038/nrd.2015.35.
    [20] ZHU SG, LI HB, YUAN ZN, et al. Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: A case report[J]. World J Gastrointest Oncol, 2020, 12(10): 1209-1215. DOI: 10.4251/wjgo.v12.i10.1209.
  • 加载中
图(4)
计量
  • 文章访问数:  523
  • HTML全文浏览量:  167
  • PDF下载量:  42
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-07-24
  • 出版日期:  2022-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回